EPIDEMIOLOGY 200B Methods II – Prediction and Validity Scott P. Layne, MD

1. EPIDEMIOLOGY 200BMethods II – Prediction and ValidityScott P. Layne, MD

2. PART 3Human Immunodeficiency virusEpidemic Between Hosts March 2010

3. TWO EPIDEMICS Between people HIV is a risk-based disease Not all individuals are at equal risk Within people HIV-1 & HIV-2 disable the immune system Predisposes to opportunistic infections & cancer

4. GLOBAL VIEW 2.0 M HIV/AIDS deaths (2007) male-to-female ratio ~ 1 30 - 36 M living with infection (2007) male-to-female ratio ~ 1 2.0 million children < 15 years 2.7 M new infections (2007) male-to-female ratio ~ 1 0.4 million children < 15 years

5. GLOBAL VIEW Becoming #1 infectious disease killer in the world In the US, HIV is #2 cause of death in men 25 - 44 years Millions to billions of viral genotypes Antiviral therapies expensive Antiviral resistance increasing Vaccine trials underway but promise unclear

7. CLINICAL FEATURES HIV progressive, chronic disease Infections irreversible, not curable Progression associated with HIV loads Higher viral loads cause faster CD4 cell declines Lower viral loads cause slower CD4 cell declines Viral loads < 102 associated with slower declines Viral loads > 104 associated with faster declines

8. CELLULAR MARKER Normal CD4 counts (range) 900 - 1800 per mm3 Untreated HIV infection Decline is 50 - 80 per year AIDS diagnosis at 180 per mm3 on average (MACS). Immunodeficiency CD4 counts < 200 per mm3 Opportunistic infections CD4 counts < 50 per mm3

10. DISEASE PHASES Acute retroviral syndrome 50 – 90% of cases Occurs 2 – 4 weeks post exposure Asymptomatic period 50% develop significant disease within 10 years Symptomatic period 1. Persistent generalized lymphadenopathy (PGL)

11. DISEASE PHASES Symptomatic period (cont.) 2. AIDS related complex (ARC) Fever Fatigue Diarrhea Weight loss Night sweats 3. Full blown AIDS Opportunistic infections Malignancies Progressive wasting Encephalopathy

12. OPPORTUNISTIC INFECTIONS Pneumocystis carinii pneumonia Toxoplasmosis encephalopathy Cryptosporidia profuse diarrhea Cryptococcus neoformans meningitis Candida albicans esophagitis Histoplasmosis disseminated Mycobacterium tuberculosis pneumonia, disseminated Mycobacterium avium pneumonia Herpes simplex mucocutaneous ulcers Cytomegalovirus pneumonia, retinitis, gastroenteritis Varicella-zoster localized, disseminated

13. FURTHER MANIFESTATIONS Malignancies Kaposi’s Sarcoma Non-Hodgkin’s lymphoma Neurological AIDS dementia Memory Loss Depression Seizures and Coma Wasting Slim disease Severe intractable wasting & diarrhea More common in Africa Associated with mix of opportunistic infections

14. OUTCOMES AIDS Mortality, pre-antiretrovirals 75% mortality within 2 years after AIDS diagnosis Today Drug treatments have slowed progression to AIDS Recent advances have not reduced mortality rates

15. EPIDEMIOLOGY Transmission routes Overall by intimate contact Primarily heterosexual contact worldwide No evidence of airborne, vector transmission Transmission probabilities Sexual (per contact) 0.001 – 0.004 (developed countries) 0.041 – 0.075 (female-to-male in Thailand) Sexual (per partner) 0.1 – 0.2 (homosexual) Perinatal (per birth) 0.25 – 0.40 for HIV-positive mothers Parenteral (per needle-stick) 0.002 – 0.004 for health workers

16. EPIDEMIOLOGY Transmission probability increased by Breaks in epithelial surface Presence of ulcerative STDs Lack of circumcision Receptive anal intercourse Multiple partners Fragile mucosa of rectum Various HIV phenotypes / genotypes ?

17. EPIDEMIOLOGY Human ID-50 Undefined Cell-free vs cell-associated virus Relative contributions of each are not determined May depend on the particular route of transmission HIV found in body fluids Plasma Semen Cervical secretions Breast milk Saliva Tears

18. MODEL DEVELOPMENT

19. KEY CONCEPTS Initial growth of the AIDS epidemic in the United States Rate that people become infected with HIV Rate that people progress to AIDS Prior to antiretrovirals Prior to opportunistic infection prophylaxis Why is this easier than today?

20. Cumulative AIDS cases plotted as the cube root versus time as reported by the CDC. Race: 1) White; 2) Black; 3) Hispanic; 4) Unknown.

21. KEY CONCEPTS Risk-based disease Risk is not distributed equally among the population Behavorial mixing People with similar risk tend to interact among themselves Biased mixing People interact equally with others Unbiased mixing Which one is it?

22. Distribution of new partner rate for homosexual men attending sexually transmitted disease clinics in London.

23. The distribution of males (adolescent to 30) versus sexual outlet frequency. Data from Kinsey, 1948.

24. HIV —> AIDS Probability 6% per year 0 2 6 Probability of developing AIDS over time. Source: San Francisco Hepatitis B Study, 1988

25. T = 0 Biased mixing vs Unbiased mixing Number Risk Susceptible Infection

26. T = 1 Number Risk

27. T = 2 Number Saturate Risk

28. T = 3 Number Saturate Risk

29. T = 4 Number Infection Wave Risk

30. T = 5 Number Risk

31. Calculation of fraction infected versus risk behavior when mixing is biased at various times (t = 5, 10, 15, ... 40 units)

32. Homogenous Mixing The fastest growth of infection of infection occurs in average risk group Early growth is nearly exponential and larger than biased mixing case Calculation is not consistent with CDC observations

33. Calculation of fraction infected when mixing is homogeneous at various times (t = 5, 10, 15, ... 40 units)

34. Biased Mixing Infection grows to saturation in the highest risk group and moves progressively to lower risk groups Calculation is consistent with CDC observations

35. IMPLICATIONS & INSIGHTS Vaccines Define efficacy as probability of preventing infection Vaccine shifts or rescales peoples' position in risk-space Even with highly effective vaccines, high-risk people will maintain transmission STDs and core groups

36. Vaccine given at T = 5 Number Risk

37. T = 6 Number Infection Wave Risk

38. PREVENTION HIV transmission is risk-based Identify the risks that are associated with transmission Intervene and modify the risks that facilitate transmission

39. PREVENTION Modify sexual behavior Number of partners Type of practices Safe sex practices and failure rates (condoms) Reduce co-factors Sexually transmitted diseases Programs to identify and treat STDs Intravenous drugs Reduce abuse Reduce sharing of injection equipment Promote disinfection of injection equipment Provide clean injection equipment

40. PREVENTION Disruption of family and tribal units Education to modify behaviors Technology Reduce cost of HIV testing Make HIV testing more widely available Rapid testing Vaccines Phase III trials underway / promise? Variability of the viral genome is a problem Selecting viral strain for vaccine is a problem Not clear which immune responses are protective False sense of protection that increases infection

41. READING Stirling A. Colgate, et al. 1989. Risk behavior-based model of the cubic growth of acquired immunodeficiency syndrome in the United States. Proc. Natl. Acad. Sci. USA 86, 4793 – 4797.